体外临床前模型评估用于治疗视网膜母细胞瘤药物的预测能力。

The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma.

作者信息

Sinenko Irina L, Turnell-Ritson Roland C, Munier Francis L, Dyson Paul J

机构信息

Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland; Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, CH-1004, Lausanne, Switzerland.

Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland.

出版信息

Exp Eye Res. 2023 May;230:109447. doi: 10.1016/j.exer.2023.109447. Epub 2023 Mar 20.

DOI:10.1016/j.exer.2023.109447

PMID:36940901

Abstract

Retinoblastoma is a rare childhood cancer of the eye. Of the small number of drugs are used to treat retinoblastoma, all have been repurposed from drugs developed for other conditions. In order to find drugs or drug combinations better suited to the improved treatment of retinoblastoma, reliable predictive models are required, which facilitate the challenging transition from in vitro studies to clinical trials. In this review, the research performed to date on the development of 2D and 3D in vitro models for retinoblastoma is presented. Most of this research was undertaken with a view to better biological understanding of retinoblastoma, and we discuss the potential for these models to be applied to drug screening. Future research directions for streamlined drug discovery are considered and evaluated, and many promising avenues identified.

摘要

视网膜母细胞瘤是一种罕见的儿童眼部癌症。在用于治疗视网膜母细胞瘤的少数药物中，所有药物都是从为其他病症开发的药物重新利用而来。为了找到更适合改善视网膜母细胞瘤治疗的药物或药物组合，需要可靠的预测模型，这有助于实现从体外研究到临床试验这一具有挑战性的转变。在本综述中，介绍了迄今为止在视网膜母细胞瘤二维和三维体外模型开发方面所进行的研究。这项研究大多是为了更好地从生物学角度理解视网膜母细胞瘤，我们还讨论了这些模型应用于药物筛选的潜力。对简化药物发现的未来研究方向进行了思考和评估，并确定了许多有前景的途径。